{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:25Z","timestamp":1781647225934,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glypican-3 (GPC-3) is a promising biomarker and therapeutic target in hepatocellular carcinoma (HCC), yet its noninvasive preoperative assessment remains challenging. This study developed and validated a nomogram model integrating contrast-enhanced ultrasound (CEUS) features with clinical variables to predict GPC-3 expression and assess its prognostic significance for recurrence-free survival (RFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of 316 HCC patients who underwent preoperative CEUS was performed. Predictive CEUS features and clinical variables were identified using least absolute shrinkage and selection operator regression and multivariable logistic regression. The nomogram was constructed and validated in training and validation cohorts, with performance assessed by receiver operating characteristic curve, calibration curves, and decision curve analysis. Kaplan-Meier and Cox regression analyses were used to assess the association between GPC-3 expression, nomogram scores, and RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age of the patients was 59 years (IQR, 52\u201367 years), with a predominance of male patients (267\/316, 84.49%). Four predictors of GPC-3 expression were identified: alpha-fetoprotein, feeding artery, hyper-enhanced rim in the arterial phase, and necrosis. The nomogram achieved area under the curve values of 0.90 (95% CI: 0.86, 0.94) in the training cohort and 0.88 (95% CI: 0.80, 0.94) in the validation cohort. The positive predictive value and negative predictive value were 97.14% (95% CI: 94.38, 99.90) and 54.32% (95% CI: 43.47, 65.17) in the training cohort, and 96.77% (95% CI: 91.80, 99.99) and 45.46% (95% CI: 28.12, 62.08) in the validation cohort, respectively. Calibration plots and decision curve analysis confirmed its clinical utility. GPC-3 expression was identified as an independent prognostic factor for RFS (hazard ratio: 3.56; 95% CI: 2.18, 5.83), and patients with high nomogram scores had significantly shorter RFS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This CEUS-based nomogram provides an accurate, noninvasive method for predicting GPC-3 expression and RFS in HCC patients, serving as a valuable tool for personalized treatment strategies and optimizing GPC-3-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01033-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:34:14Z","timestamp":1775900054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Noninvasive prediction of glypican-3 expression and recurrence-free survival in hepatocellular carcinoma using contrast-enhanced ultrasound"],"prefix":"10.1186","volume":"26","author":[{"given":"Lianhua","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"1033_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1033_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.scib.2025.02.006","volume":"70","author":"H Li","year":"2025","unstructured":"Li H, Li Q, Zheng Y, He S, Teng Y, Cao M, et al. Profiles and disparities of the global cancer and subtypes burden among adults aged 65 years and older: changing patterns in incidence and mortality, 1990\u20132021. Sci Bull (Beijing). 2025;70:1139\u201351.","journal-title":"Sci Bull (Beijing)"},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386\u2013401.","journal-title":"Nat Cancer"},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"106652","DOI":"10.1016\/j.ijsu.2022.106652","volume":"102","author":"K Liao","year":"2022","unstructured":"Liao K, Yang K, Cao L, Lu Y, Zheng B, Li X, et al. Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial. Int J Surg. 2022;102:106652.","journal-title":"Int J Surg"},{"key":"1033_CR5","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","volume":"63","author":"F Qihan","year":"2023","unstructured":"Qihan F, Yi Z, Weijia F, Qingwei Z, Peng Z, Lulu L, et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine. 2023;63:102175.","journal-title":"EClinicalMedicine"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.acra.2022.04.006","volume":"30","author":"H Chong","year":"2023","unstructured":"Chong H, Gong Y, Zhang Y, Dai Y, Sheng R, Zeng M. Radiomics on gadoxetate disodium-enhanced MRI: non-invasively identifying glypican 3-positive hepatocellular carcinoma and postoperative recurrence. Acad Radiol. 2023;30:49\u201363.","journal-title":"Acad Radiol"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"2010894","DOI":"10.1080\/2162402X.2021.2010894","volume":"11","author":"L Shao","year":"2022","unstructured":"Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. Oncoimmunology. 2022;11:2010894.","journal-title":"Oncoimmunology"},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/cas.14497","volume":"111","author":"M Taniguchi","year":"2020","unstructured":"Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, et al. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747\u201359.","journal-title":"Cancer Sci"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1007\/s00261-025-04861-8","volume":"50","author":"F Huang","year":"2025","unstructured":"Huang F, Pang J, Wu Y, Sun Y, Wen R, Bai X, et al. Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma. Abdom Radiol (NY). 2025;50:5187\u201396.","journal-title":"Abdom Radiol (NY)"},{"key":"1033_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/RLI.0000000000001022","volume":"59","author":"C Krolak","year":"2024","unstructured":"Krolak C, Dighe M, Clark A, Shumaker M, Yeung R, Barr RG, et al. Quantification of hepatocellular carcinoma vascular dynamics with contrast-enhanced ultrasound for LI-RADS implementation. Invest Radiol. 2024;59:337\u201344.","journal-title":"Invest Radiol"},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"e251698","DOI":"10.1148\/radiol.251698","volume":"317","author":"L Zhu","year":"2025","unstructured":"Zhu L, Jiang B, Fei X, Xu Y, Liu Z, Zhang W, et al. Contrast-enhanced US evaluation of residual hepatocellular carcinoma following lenvatinib combined with anti-PD-1 antibody downstaging therapy. Radiology. 2025;317:e251698.","journal-title":"Radiology"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"e230727","DOI":"10.1148\/radiol.230727","volume":"309","author":"E Savsani","year":"2023","unstructured":"Savsani E, Shaw CM, Forsberg F, Wessner CE, Lyshchik A, O\u2019Kane P, et al. Contrast-enhanced US evaluation of hepatocellular carcinoma response to chemoembolization: a prospective multicenter trial. Radiology. 2023;309:e230727.","journal-title":"Radiology"},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15212\/bioi-2023-0019","volume":"5","author":"H Qin","year":"2024","unstructured":"Qin H, Ji Z, Zhao Q, Wang K, Mao F, Han H, et al. Contrast-enhanced ultrasound features of primary hepatic lymphoepithelioma-like carcinoma: comparison with hepatocellular carcinoma. BIOI. 2024;5:1\u20137.","journal-title":"BIOI"},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ultrasmedbio.2023.02.020","volume":"49","author":"B Jiang","year":"2023","unstructured":"Jiang B, Fei X, Fan X, Zhu L, Lu S, Luo Y. A nomogram based on contrast-enhanced ultrasound to predict the microvascular invasion in hepatocellular carcinoma. Ultrasound Med Biol. 2023;49:1561\u20138.","journal-title":"Ultrasound Med Biol"},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13244-024-01821-6","volume":"15","author":"X Fei","year":"2024","unstructured":"Fei X, Zhu L, Han P, Jiang B, Li M, Li N, et al. Value of high frame rate contrast-enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma. Insights Imaging. 2024;15:273.","journal-title":"Insights Imaging"},{"key":"1033_CR16","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1007\/s00330-023-09656-3","volume":"33","author":"J Yao","year":"2023","unstructured":"Yao J, Li K, Yang H, Lu S, Ding H, Luo Y, et al. Analysis of sonazoid contrast-enhanced ultrasound for predicting the risk of microvascular invasion in hepatocellular carcinoma: a prospective multicenter study. Eur Radiol. 2023;33:7066\u201376.","journal-title":"Eur Radiol"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/a-1177-0530","volume":"41","author":"CF Dietrich","year":"2020","unstructured":"Dietrich CF, Nols\u00f8e CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020;41:562\u201385.","journal-title":"Ultraschall Med"},{"key":"1033_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1148\/radiol.212317","volume":"305","author":"W Wu","year":"2022","unstructured":"Wu W, Jing X, Xue GQ, Zhu XL, Wang J, Du RQ, et al. A multicenter randomized controlled study of contrast-enhanced US versus US-guided biopsy of focal liver lesions. Radiology. 2022;305:721\u20138.","journal-title":"Radiology"},{"key":"1033_CR19","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1186\/s12885-025-14907-1","volume":"25","author":"L Zhu","year":"2025","unstructured":"Zhu L, Li N, Liang S, Jiang B, Li M, Luo Y, et al. High frame rate contrast-enhanced ultrasound in hepatocellular carcinoma: biological characteristics and patient outcomes. BMC Cancer. 2025;25:1488.","journal-title":"BMC Cancer"},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.acthis.2008.11.025","volume":"112","author":"H Takai","year":"2010","unstructured":"Takai H, Kato A, Ishiguro T, Kinoshita Y, Karasawa Y, Otani Y, et al. Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochem. 2010;112:240\u201350.","journal-title":"Acta Histochem"},{"key":"1033_CR21","doi-asserted-by":"publisher","first-page":"973153","DOI":"10.3389\/fimmu.2022.973153","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Qin Y, Wu Y, Wei H, Wei Y, Zhang Z, et al. Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging. Front Immunol. 2022;13:973153.","journal-title":"Front Immunol"},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/JS9.0000000000001883","volume":"111","author":"Y Duan","year":"2025","unstructured":"Duan Y, Du Y, Mu Y, Guan X, He J, Zhang J, et al. Development and validation of a novel predictive model for postpancreatectomy hemorrhage using lasso-logistic regression: an international multicenter observational study of 9631 pancreatectomy patients. Int J Surg. 2025;111:791\u2013806.","journal-title":"Int J Surg"},{"key":"1033_CR23","doi-asserted-by":"publisher","first-page":"116047","DOI":"10.1016\/j.ejmech.2023.116047","volume":"264","author":"Y Fang","year":"2024","unstructured":"Fang Y, Ma H, Zhang X, Zhang P, Li Y, He S, et al. Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma. Eur J Med Chem. 2024;264:116047.","journal-title":"Eur J Med Chem"},{"key":"1033_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","volume":"38","author":"F Zhou","year":"2018","unstructured":"Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741\u201367.","journal-title":"Med Res Rev"},{"key":"1033_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3233\/CH-231912","volume":"85","author":"N Li","year":"2023","unstructured":"Li N, Dong T, Wang P, Li Q, Nie F. Predicting glypican-3 expression in hepatocellular carcinoma: a comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors. Clin Hemorheol Microcirc. 2023;85:407\u201320.","journal-title":"Clin Hemorheol Microcirc"},{"key":"1033_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12880-024-01408-z","volume":"24","author":"RM Ahmed","year":"2024","unstructured":"Ahmed RM, Ali WA, AbdelHakam AM, Ahmed SH. Detection of hepatocellular carcinoma feeding vessels: MDCT angiography with 3D reconstruction versus digital subtraction angiography. BMC Med Imaging. 2024;24:250.","journal-title":"BMC Med Imaging"},{"key":"1033_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejrad.2016.12.030","volume":"88","author":"H Zhao","year":"2017","unstructured":"Zhao H, Hua Y, Dai T, He J, Tang M, Fu X, et al. Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma. Eur J Radiol. 2017;88:32\u201340.","journal-title":"Eur J Radiol"},{"key":"1033_CR28","doi-asserted-by":"publisher","first-page":"109732","DOI":"10.1016\/j.ejrad.2021.109732","volume":"139","author":"J Zhao","year":"2021","unstructured":"Zhao J, Gao S, Sun W, Grimm R, Fu C, Han J, et al. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. Eur J Radiol. 2021;139:109732.","journal-title":"Eur J Radiol"},{"key":"1033_CR29","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu R, Li P, Chen X, Zhang J, Yu Q, et al. Preoperative prediction of glypican-3 in hepatocellular carcinoma by two-dimensional ultrasound, contrast-enhanced ultrasound and microflow imaging. Clin Hemorheol Microcirc. 2025:13860291251376273.","DOI":"10.1177\/13860291251376273"},{"key":"1033_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41419-020-03030-7","volume":"11","author":"T Chen","year":"2020","unstructured":"Chen T, Dai X, Dai J, Ding C, Zhang Z, Lin Z, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas\/FADD apoptotic pathway. Cell Death Dis. 2020;11:822.","journal-title":"Cell Death Dis"},{"key":"1033_CR31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/hep.21825","volume":"46","author":"LA Morford","year":"2007","unstructured":"Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology. 2007;46:1541\u20137.","journal-title":"Hepatology"},{"key":"1033_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"K Du","year":"2021","unstructured":"Du K, Li Y, Liu J, Chen W, Wei Z, Luo Y, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther. 2021;29:1572\u201384.","journal-title":"Mol Ther"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01033-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:50:20Z","timestamp":1781646620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01033-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01033-9","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committees of Chinese PLA General Hospital (Approval No. S2024-369-01), and informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}